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Abstract 
Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results 
in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of 
omalizumab in CSU has not been elucidated in detail. 
Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI+) 
and IgE-positive (IgE+) dermal cells and blood basophils. Treatment efficacy and safety were also assessed. 
Study design. In a double-blind study, CSU patients aged 18-75 years were randomized to receive 300 mg 
omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks. Changes in disease 
activity were assessed by use of the weekly Urticaria Activity Score (UAS7). Circulating IgE levels, basophil 
numbers and levels of expression of FcεRI+ and IgE+ cells in the skin and in blood basophils were determined.  
Results. Patients receiving omalizumab showed a significantly greater decrease in UAS7 compared with 
patients receiving placebo. At Week 12 the mean difference in UAS7 between treatment groups was -14.82 
(p=0.0027), consistent with previous studies.  
Total IgE levels in serum were increased after omalizumab treatment and remained elevated up to Week 12. 
Free IgE levels decreased after omalizumab treatment. 
Mean levels of FcεRI+ skin cells in patients treated with omalizumab 300 mg were decreased at Week 12 
compared with baseline in the dermis of both non-lesional and lesional skin, reaching levels comparable with 
those seen in healthy volunteers (HVs). There were no statistically significant changes in mean FcɛRI+ cell 
levels in the placebo group. Similar results were seen for changes in IgE+ cells, although the changes were not 
statistically significant.  
The level of peripheral blood basophils increased immediately after treatment start and returned to Baseline 
values after the follow-up period. The levels of FcεRI and IgE expression on peripheral blood basophils were 
rapidly reduced by omalizumab treatment up to Week 12. 
Conclusions. Treatment with omalizumab resulted in rapid clinical benefits in patients with CSU. Treatment 
with omalizumab was associated with reduction in Fcɛ RI+ and IgE+ basophils and intradermal cells. 










Omalizumab (Xolair®) is a recombinant 
humanized monoclonal antibody that binds to IgE at 
its binding site to the high-affinity IgE receptor (FcεRI) 
[1]. Free IgE levels fall between 89 to 98% over 16 to 24 
weeks of therapy. Associated with the decrease in free 
IgE levels is a down-regulation in the expression of 
FcεRI receptors on basophils and mast cells [2-4]. In 
addition, recent data show that omalizumab is able to 
dissociate pre-bound IgE from mast cells and 
basophils [5, 6].  
Omalizumab is effective in the treatment of 
chronic spontaneous / idiopathic urticaria (CSU / 
CIU) [7-13] including in patients who have relapsed 
after stopping treatment with omalizumab [14]. 
Omalizumab is approved for the treatment of CSU (in 
the EU) and CIU (in the USA) patients who remain 
symptomatic despite H1-antihistamine treatment [15, 
16].  
Urticaria is characterized by the development of 
hives, angioedema, or both [17]. Pathogenesis of CSU 
is not fully understood [17]. It appears to be a mast 
cell- and basophil-mediated hypersensitivity reaction 
[18-22]. Histamine and other mediators are released 
on activation of basophils and mast cells, and these 
mediators ultimately give rise to the clinical signs and 
symptoms of CSU. The pathology of CSU lesions 
resembles that of allergen-mediated late-phase skin 
reactions, suggesting involvement of FcεRI activation 
of mast cells and basophils [23]. Antigen cross-linking 
of IgE bound to FcεRI is a known mediator of basophil 
and mast cell activation [24]. Also, approximately 45% 
of CSU patients have histamine-releasing 
autoantibodies against either FcεRI or IgE [25, 26]; the 
clinical significance is unclear, but as cross-linking of 
IgE or FcεRI on mast cell or basophil surface may 
result in activation and release of inflammatory 
mediators [27-29], these antibodies may be involved 
in disease pathogenesis [30, 31]. It has also been 
suggested that basophils in CSU patients may have 
distinct alterations in FcεRIα mediated degranulation, 
independent of any role of autoantibodies [32-34]. 
Little is known about the effects of omalizumab 
on basophil numbers and function in CSU. A previous 
skin biopsy study in patients with allergic rhinitis [4] 
showed that omalizumab treatment was associated 
with a decrease in the number of FcεRI+ mast cells in 
the skin and basophils in the blood, and that this was 
associated with a reduction in the size of 
allergen-induced hives in intradermal skin tests. 
Treatment with omalizumab reduced serum IgE and 
IgE+ cells in the airway mucosa of patients with 
allergic asthma [35]. The effects of omalizumab on 
basophils from the circulation of CSU patients has 
been described before [36] but little is known about 
local effects of omalizumab treatment in the skin. 
Therefore, the current study took biopsies from 
lesional and non-lesional skin of CSU patients, to 
evaluate the effects of treatment with omalizumab on 
basophil numbers and levels of FcεRI+ and IgE+ skin 
cells in CSU patients compared with that of skin from 
healthy volunteers.  
Methods  
This was an exploratory, double-blind, parallel 
group, randomized, placebo-controlled Phase II study 
(NCT01599637, EudraCT no. 2011-004216-31; Figure 
1). Patients were enrolled at 4 centers in Germany. 
The study was conducted in accordance with 
applicable local regulations (including European 
Directive 2001/20/EC, US Code of Federal 
Regulations Title 21, and Japanese Ministry of Health, 
Labor, and Welfare), the International Conference on 
Harmonization E6 Guideline for Good Clinical 
Practice, and the ethical principles of the Declaration 
of Helsinki. The study protocol and all amendments 
were reviewed by the Independent Ethics Committee 
(IEC) or Institutional Review Board (IRB) for each 
center and written informed consent was obtained 
from study participants before enrollment. 
Study design 
For CSU patients, the study consisted of a 10-day 
screening period, during which patient eligibility for 
study entry was assessed, followed by a 3-day 
washout period and a 14-day baseline period (Figure 
1). During this period, urticaria activity was assessed. 
In patients who had taken rescue medication due to 
high disease activity (a short-acting, non-sedating 
antihistamine), the following day was not counted in 
order to exclude any carry-over effect. However, if the 
urticaria activity score (UAS) for that day was 6, the 
day was counted irrespective of medication use on the 
previous day. For the calculation of the baseline UAS7 
seven individual days were calculated counting 
backwards, beginning with the last day before 
randomization. The treatment period was 12 weeks; 
on Day 1 of the treatment period, patients were 
randomized in a 2:1 ratio to omalizumab 300 mg or 
placebo (3 subcutaneous doses at 4-weekly intervals, 
i.e. at Day 1, Week 4 and Week 8). After stopping the 
treatment, patients were followed for an additional 8 
weeks (follow-up). The total duration of the study per 
patient was approximately 23 weeks. Skin biopsies 
were taken from CSU patients at baseline, Week 1, 





Week 4 (optional), Week 12, and Week 20 (after 
follow-up) from non-lesional and lesional skin (as 
available). The optional biopsy at Week 4 was taken 
from patients who showed response to treatment at 
that time-point (defined as UAS7 ≤6), while no 
response (UAS7 ≥16) was seen at Week 1. On dosing 
days (Day 1 and Day 29), biopsies were taken 
pre-dose and blood samples were taken for 
measurement of basophils. The eligibility of the 
healthy volunteers (HVs) was assessed at a screening 
visit, then at Day 1 a single skin biopsy was collected 
and study completion assessments performed.  
Study population 
The study included patients, aged 18 to 75 years, 
diagnosed with CSU who remained symptomatic 
despite H1-antihistamine treatment at approved 
doses, defined as presence of itch and hives for over 6 
weeks prior to baseline, with UAS7 score of at least 16 
and itch component of UAS7 of at least 8 during the 14 
days prior to randomization. Patients had to have had 
a CSU diagnosis for at least 6 months, and be on an 
approved dose of an H1-antihistamine for CSU prior 
to entering the study. 
Exclusion criteria included weight >130 kg or 
<40 kg at screening; heavy smoking; chronic urticaria 
other than CSU; diseases with symptoms of urticaria 
or angioedema (e.g. urticarial vasculitis, urticaria 
pigmentosa, erythema multiforme, mastocytosis, 
hereditary or acquired angioedema, lymphoma, 
leukemia, or generalized cancer); history or presence 
of atopic dermatitis, bullous pemphigoid, dermatitis 
herpetiformis, senile pruritus or other skin disease 
associated with itch; evidence of parasitic infection; 
any clinically relevant major systemic disease that 
could potentially complicate interpretation of study 
results; and inability to comply with study and 
follow-up procedures. All subjects (both CSU patients 
and controls) with asthma and atopic dermatitis were 
excluded. History of clinically significant 
hypersensitivity to omalizumab or similar drugs, or to 
local anesthetics, and history of anaphylactic shock 
were also exclusion criteria. 
Patients were not allowed to be using other 
investigational drugs at the time of randomization 
(Day 1), or within 30 days or 5 half-lives of 
enrollment, whichever was longer; could not have 
had previous treatment with omalizumab; could not 
be receiving routine doses of systemic or topical 
corticosteroids, hydroxychloroquine, methotrexate, 
cyclosporine, cyclophosphamide or any other 
immunomodulating drug (e.g. interferons) that could 
alter the response to omalizumab treatment, or IV 
immunoglobulin G, or plasmapheresis within 30 days 
prior to -2 weeks. Regular oral doxepin use within 6 
weeks prior to -2 weeks, use of any H2 antihistamine 
or any leukotriene receptor antagonists (LTRAs) 
within 7 days prior to -2 weeks, or use of any H1 
antihistamines at greater than approved doses within 
3 days prior to -2 weeks were also not permitted. 
Patients needed to be on stable doses for 4 weeks prior 
to randomization (Day 1). Loratadine (a short-acting, 
non-sedating antihistamine), was allowed to be used 
as a rescue medication on an as needed basis up to 4 
times the recommended dose of 10 mg, for 
angioedema or other reasons specified by the patient. 
The use of loratadine was documented by the patient 




Figure 1. Study design. 





Age and gender-matched healthy volunteers 
participated in the study to the CSU patients, and 
were in good health. Exclusion criteria for healthy 
volunteers were similar to those for CSU patients 
(except for those criteria specifically related to 
urticaria and its treatment), with the addition of the 
use of any prescription drug or over-the-counter 
medication within 2 weeks prior to Day 1 
(paracetamol was acceptable, but its use had to be 
documented). 
Study endpoints 
The primary variable was the relative change 
from baseline to Week 12 in the FcεRI+ and/or IgE+ 
skin cells, based on skin biopsies collected from CSU 
patients. Skin biopsy data from healthy volunteers 
were used as a reference for data from CSU patients.  
Assessments 
Clinical efficacy and quality of life were assessed 
using UAS7, patient’s and investigator’s global 
assessment of symptoms using a graded Likert scale 
scoring of symptoms (urticaria lesions [hives] and 
itch), angioedema, Dermatology Life Quality Index 
(DLQI), Skindex-29, and Chronic Urticaria Quality of 
Life Questionnaire (CU-Q2OL) [37]. 
Patient symptoms of itch and hives were 
recorded via electronic diary (eDiary) each morning 
and evening on a daily basis to assess UAS. The 
composite eDiary−recorded score with numeric 
severity intensity ratings on a scale of 0−3 (0 = none to 
3 = intense/severe) for the number of hives and the 
intensity of itch. Daily UAS was calculated as the 
average of the morning and evening scores; UAS7 is 
the sum of the daily UAS scores over 7 days. Response 
to treatment was defined as a 90% reduction from 
baseline in UAS7, a cut-off previously used to 
illustrate complete response in a retreatment study 
[14]. 
Safety was assessed in terms of the frequency 
and severity of adverse events (AEs), vital signs, ECG 
evaluations, and clinical laboratory measurements. 
Serum omalizumab concentrations were evaluated 
using a validated ELISA method with an anticipated 
Lower Limit of Quantification (LLOQ) of 28 ng/mL. 
Measurement of basophils 
Blood samples were taken and incubated with 
antibodies (Lineage cocktail-FITC [Becton Dickinson], 
CD203c/PerCPCy5.5 [Biolegend], IgE-PE [Biolegend] 
and FcεR1-APC [eBioscience]) at RT, fixed with 1% 
paraformaldehyde in phosphate buffered saline (PBS) 
and the samples stored frozen at -80°C before 
shipment on dry ice to a central processing laboratory. 
Thawed samples were processed as follows: after 
centrifugation for 7 min at 500g at RT, the pellets were 
washed and aspirated twice, before being 
resuspended in 200μl 1% paraformaldehyde in PBS. 
They were then analyzed within 4 hours by 
fluorescent antibody cell sorting (FACS) performed 
on a FACS-Canto II (Becton Dickinson, CA, USA) 
using the FACSDiva software after adjustment with 
antibodies bound to compensation particles. Mean 
values and the coefficient of variation (CV) were 
calculated and a CV <30% was acceptable. 
Analysis of IgE 
Blood samples were collected into additive free 
tubes and allowed to clot over a minimum of 30 min 
at room temperature (RT). Serum was collected after 
centrifugation at approximately 3500 rpm for 10 min. 
Serum samples were split into 2 aliquots and stored at 
-20°C until analysis at the central laboratory. Serum 
levels of free IgE and total IgE (i.e. the sum of free and 
bound IgE) were determined by specific 
immunoassays, as described previously [38]. 
Biopsies 
Patients provided biopsies from non-lesional 
and lesional skin (as available). An optional biopsy 
could be performed at Week 4; this was targeted at 
slower responding patients and therefore the 
numbers of biopsies collected at this time-point 
depended on response to treatment. Skin biopsies 
with a minimum diameter of 6 mm were taken at each 
scheduled time-point. Baseline biopsies were taken 
from one location with lesional skin and from one 
with non-lesional skin. Following treatment, biopsies 
were taken at locations close to the locations chosen at 
baseline. Biopsy samples were stored at -80°C until 
sectioned. 
Histopathology procedures 
Biopsy samples were examined using 
immunohistochemistry techniques. Samples from 
skin biopsies were sectioned (5 µm) with a cryostat at 
approximately -21°C and placed on glass slides. After 
fixing with acetone (-20°C for 10 min), sections were 
dried and kept at -20°C. Staining (IHC, Giemsa, or 
H&E) was carried out on thawed samples.  
Immunohistochemical staining with alkaline 
phosphatase (AP) was performed to analyze FcεRI 
and IgE. Samples were thawed and blocked 
sequentially with biotin and avidin for 15 mins at RT, 
followed by 2% fetal calf serum (FCS) in Tris-buffered 
saline (TBS) for 20 mins at RT. Samples were then 
incubated with specific primary antibodies, diluted in 
TBS + 1% FCS for 1 hour at RT: mouse anti-CD117 (BD 
555713), diluted 1:400; mouse anti-CD11c (BD 550375) 
diluted 1:400; mouse anti-CD8 (DakoM7103) diluted 
1:150; mouse anti CD4 (Dako M7310) diluted 1:200; 
mouse anti-CD3 (Dako (M7254) diluted 1:400; mouse 





anti FCεR1 (eBioscience 14-5899) diluted 1:400; mouse 
anti-tryptase (Dako M7052) diluted 1:500; or rabbit 
anti-IgE (Dako A0094) diluted 1:5000. Negative 
control staining was carried out using the same 
concentration of IgG1 (Dako X0931), IgG2bk 
(eBioscience 14-4732) or rabbit IgG (Dako X0936). 
Samples were then incubated with a biotinylated 
secondary antibody (Link Antibody ready to use, 
Dako REAL Detection System K50050) for 15 mins at 
RT, then with streptavidin-alkaline phosphatase 
(Dako REAL Detection System K5005) for 15 mins at 
RT, then with levamisole for 15 mins at RT before 
being counterstained with hematoxylin for 5 seconds 
at RT and mounted in aqueous solution.  
Hematoxylin and eosin staining was carried out 
on cryosections using Papanicolaous Solution 1a 
Harris’ hematoxylin solution (Merck # 1.09253.2500) 
and Eosin-Phloxin Solution (Hollborn, 1 L, # 601017). 
Samples were mounted in Clarion environmentally 
safe permanent mounting media. 
Alkaline Giemsa-Staining was carried out on 
cryosections using Giemsa Azur Eosin-Methylenblau 
1:10 with 2% sodium borate solution before mounting 
with Clarion environmentally safe permanent 
mounting media. 
Skin biopsy samples were scored on an average 
number of positive cells from 5 visual fields. 
Data analyses 
Analyses of cellular data were based on the 
pharmacodynamic (PD) analysis population, which 
included all subjects who received at least one dose of 
study drug and had evaluable PD data. The primary 
variable was the relative change from baseline in 
FcεRI+ and/or IgE+ skin cells, based on skin biopsies 
collected from patients with CSU after 12 weeks of 
treatment relative to placebo. A two-tailed 
two-sample t-test was used to compare groups that 
employed a 5% significance level. 
Correlation between UAS7 and the FcεRI- and 
IgE-positive skin cells for baseline values and for the 
change from baseline to Day 85 was assessed using 
Spearman’s and Pearson’s correlation analysis. All 
results are given as two-tailed p-values, and p<0.05 
was considered statistically significant. 
All efficacy analyses were performed on the 
intent-to-treat (ITT) population which included all 
randomized patients who received at least one dose of 
study drug and had post-randomization efficacy data. 
The treatment groups were based on the treatment 
assigned at randomization. For efficacy endpoints, 
descriptive statistics were provided by treatment 
group and time-point. UAS7 was also modeled using 
a repeated measures ANCOVA model with baseline 
UAS7 score as a covariate, and treatment, time, and 
treatment by time interaction as fixed factors.  
All subjects who received at least one dose of 
study drug were included in the safety analysis. 
Results 
Disposition of participants 
Thirty patients were randomized to treatment, 
20 in the omalizumab group and 10 in the placebo 
group (Figure 2). One patient receiving omalizumab 
discontinued prematurely (due to an AE), as did two 
patients in the placebo group (due to administrative 
problems). Data were analyzed from 17 
omalizumab-treated patients and 9 patients in the 
placebo group. All 10 healthy volunteers who entered 
the study completed their single study visit. 
 
 
Figure 2. Participant flow. 
 
Participant demographics and baseline 
characteristics 
The omalizumab and placebo groups of CSU 
patients were generally well matched for 
demographic characteristics. All patients were 
Caucasian and 87% were female. The mean age was 
38.7 years, with a range of 23 to 63 years. The mean 
BMI was 27.7 kg/m2. There were four subjects with 
reported allergies in the omalizumab-treated group 
and one subject in the placebo-treated group. 
Of the 10 healthy control subjects, all were 
Caucasian and female, with a mean age of 36.4 years 
(range 24 to 51 years) and mean BMI of 24.2 kg/m2. 
UAS7 scores at baseline were comparable 
between the groups. Mean (SD) baseline serum total 
IgE concentrations were 1037 (2474) ng/mL in the 
omalizumab 300 mg group and 442 (581) ng/mL in 
the placebo group (Table 1).  





Omalizumab reduces CSU activity 
Decreases in UAS7 after omalizumab treatment 
initiation were rapid (with separation of the curves at 
Day 3) and sustained (Figure 3). At Week 12, the LS 
mean difference in UAS7 between treatment groups 
was -14.82 (p=0.0027).  
More than 50% of patients in the omalizumab 
group were UAS7 responders at Week 12 (Figure 4). 
About half of these had become responders by the end 
of Week 2. In contrast, <15% of patients receiving 
placebo had improved by Week 12, without any 
change occurring by Week 2. 
The DLQI overall score, Skindex-29 score and 
CU-Q2OL overall score all showed larger decreases 
from baseline in the omalizumab group than the 
placebo group. Mean (SD) scores at Week 12 are 
shown in Table 2. In addition, physicians’ and 
patients’ global assessment scores, itch, hives scores as 
well as loratadine use showed statistically significant 
differences between omalizumab and placebo-treated 
patients at Week 12 (Table 2).  
 
Table 1. Demographic summary. 




 N=20 N=10 N=10 
Age (years) 37.5 (11.0) 41.1 (8.0) 36.4 (9.7) 
Height (cm) 171.4 (7.3) 172.1 (10.8) 166.4 (6.3) 
Weight (kg) 78.5 (16.0) 87.4 (21.6) 66.9 (13.4) 
Female – n (%) 18 (90) 8 (80) 10 (100) 
Race Caucasian – n 
(%) 
20 (100) 10 (100) 10 (100) 
BMI (kg/m2) 26.8 (5.8) 29.3 (5.6) 24.2 (5.3) 
Baseline IgE (ng/ml) 1037 (2474) 442 (581) N/A 
Baseline UAS7 32.2 (8.0) 31.6 (7.7) N/A 
Data are provided as mean (Standard deviation) unless otherwise indicated 
Age was calculated from date of screening and date of birth 
Weight and height were taken from screening vital signs evaluations 
BMI, Body Mass Index , UAS, Urticaria Activity Score , UAS7, the sum of the daily 




Figure 3. Longitudinal UAS7 modulation by treatment.  Mean (SEM) UAS7 by treatment and week over the treatment and follow-up period (A) or by UAS 
per day during the first week of the treatment period (B). 






Figure 4. Responders to treatment. Proportion of patients with a defined 
first occurrence of UAS7 response, defined as a greater than 90% 
reduction from baseline in UAS7 score (UAS7 is the sum of the daily UAS 
scores over 7 consecutive days). 
 
Omalizumab increases total serum IgE levels 
Total serum IgE levels are known to increase 3- 
to 5-fold after omalizumab administration due to 
formation of IgE-anti-IgE complexes and altered rates 
of clearance. In this study, total IgE serum levels 
increased after the first treatment and remained 
elevated up to Week 12. The increase largely occurred 
by Day 8. No change was observed in placebo-treated 
subjects and in these subjects total IgE equals free IgE 
(Figure 5A).  
In omalizumab-treated subjects, the free IgE 
levels decreased after the first treatment and 
remained suppressed until Week 12 (Figure 5B). 
Virtually all of the decrease occurred during the first 
48 hours following treatment.  
 
Table 2. Clinical efficacy data at Week 12. 
Efficacy analysis set Mean (SD) change from baseline at Week 12 
  Omalizumab (n=17) Placebo 
(n=8) 
P-value 
Itch assessment score -11.4 (6.53) -3.8 (6.63) 0.0127 
Hives assessment score -11.6 (7.29) -3.8 (7.72) 0.0223 
Loratadine use 
(days/week) 
-1.5 (1.91) 1.3 (3.41) 0.0143 
 Mean (SD) at Week 12 
  Omalizumab Placebo 
(n=8) 
P-value 
DLQI overall score 3.8 (6.59), n=16 14.6 (10.77) 0.0058 
Skindex-29 score 6.17 (7.12), n=16 22.63 (10.28) 0.0001 
CU-Q2OL overall score 14.51 (22.32), n=17 53.53 (29.82) 0.0013 
Physician’s Global 
Assessment  
0.8 (1.01), n=17 2.0 (1.31) 0.0191 
Patient’s Global 
Assessment 
0.9 (1.05), n=17 1.9 (0.99) 0.0336 




Figure 5. Total IgE (A) and Free IgE (B) serum levels shown as mean (SEM). For serum free IgE at Day 1 (baseline), total IgE data was used. D, day; W, 
week 





Omalizumab increases peripheral blood 
basophils and reduces basophil FcεRI and IgE 
expression 
Mean levels of basophils are low in untreated 
CSU patients. In patients treated with omalizumab 
there was a non-statistically significant increase in 
peripheral blood basophils over the treatment period 
compared with placebo, mostly occurring by Week 2, 
but basophil levels returned to patients’ baseline 
values after the follow-up period (Figure 6A). 
Omalizumab treatment reduced FcεRI and IgE 
expression on peripheral blood basophils early in the 
treatment period (by Week 1) and the reduction was 
sustained through to Week 12 (Figure 6B and C). 
These values started to return towards baseline, but 




Figure 6 Changes in peripheral blood basophils during omalizumab 
treatment (mean, SEM). A: Peripheral blood basophils. B: FcεRI 
expression. C: IgE expression. (* p<0.05, **p<0.01, and ***p<0.001; NS, 
not significant).). D, day; W, week 
Omalizumab treatment normalized levels of 
FcεRI+ and IgE+ skin cells 
Mean levels of FcεRI and IgE expressing cells 
were higher in untreated CSU patients compared with 
HVs. Omalizumab, but not placebo, reduced these 
levels to those seen in HVs. In patients treated with 
omalizumab, mean levels of FcɛRI+ cells were 
statistically significantly decreased at Week 12 
compared with baseline (Day 1) in non-lesional skin 
(14.7 vs. 14.2 in HVs per visual field). Similar changes 
were observed for lesional skin (data not shown). No 
statistically significant changes in mean FcɛRI+ cell 
levels occurred in the placebo group (Figure 7). 
Similarly, mean levels of IgE+ cells in the dermis 
of the omalizumab-treated patients were reduced to 
levels comparable with those of HVs at baseline. 
Decreases from baseline to Week 12 in mean levels of 
IgE+ cells were observed in patients treated with 
omalizumab in dermis of non-lesional skin (9.80 vs. 
8.76 in HV per visual field), (Figure 7). Little 
difference was observed for lesional skin (data not 
shown).  
There was a good correlation of baseline UAS7 
scores and FcεRI-positive skin cells at baseline in 
lesional and non-lesional skin and the changes from 
baseline for these two parameters correlated for the 
non-lesional skin. No correlations were observed 
between UAS7 and IgE-positive skin cells at baseline 
but changes in UAS7 correlated with changes in 
IgE-positive skin cells after treatment in non-lesional 
skin as shown by Spearman correlation coefficient 
(Table 3). 
 
Table 3. Correlation between UAS7 and FcεRI-positive skin cells 
at baseline. 





Correlation between UAS7 at baseline and FcεRI-positive skin cells at 
baseline. 
Lesional skin 16 0.56 (0.02) 0.60 (0.01) 
Non-lesional skin 23 0.42 (0.04) 0.41 (0.05) 
 
Correlation between change from baseline to Day 85 for UAS7 and change 
from baseline to Day 85 in FcεRI-positive skin cells 
Lesional skin 16 0.33 (0.2) 0.24 (0.4) 
Non-lesional skin 23 0.44 (0.04) 0.38 (0.07) 
 
Correlation between UAS7 at baseline and IgE-positive skin cells at baseline 
Lesional skin 16 0.33 (0.2) 0.22 (0.4) 
Non-lesional skin 23 0.39 (0.07) 0.32 (0.1) 
 
Correlation between change from baseline to Day 85 for UAS7 and change 
from baseline to Day 85 in IgE-positive skin cells 
Lesional skin 16 0.19 (0.5) 0.15 (0.6) 
Non-lesional skin 23 0.38 (0.08) 0.45 (0.03) 
 
 






Figure 7. Mean (SEM) changes from baseline in FcεRI+ and IgE+ cells per 
visual field in biopsy samples of dermis from CSU patients. A FcεRI+ cells, 
non-lesional skin. Baseline values, mean (SD): omalizumab 18.91 (9.42); 
placebo 20.48 (5.54). B IgE+ cells, non-lesional skin. Baseline values, mean 
(SD): omalizumab 13.82 (10.21); placebo 16.59 (9.35). D, day; W, week 
 
Omalizumab is well tolerated 
Omalizumab was generally well-tolerated in this 
study. The overall incidence of AEs was slightly 
higher in the omalizumab group than in the placebo 
group (85% vs. 70%) and one person in the 
omalizumab group discontinued due to urticaria, 
which was considered mild and not considered to be 
related to study drug. The most frequently reported 
AEs overall was nasopharyngitis, which occurred at a 
similar rate in the omalizumab 300 mg and placebo 
groups. Influenza and urticaria were the next most 
frequent AEs overall and were reported at the same 
frequency in each treatment group. The AE profile 
was not unexpected in the patient population being 
studied.  
Discussion 
Omalizumab has been shown to be effective in 
the treatment of CSU, but its mechanism of action is 
not fully understood. Omalizumab decreases 
circulating levels of free IgE in the bloodstream, but 
how this pharmacodynamic effect leads to the 
alleviation of the clinical signs and symptoms is not 
completely clear. In this study, treatment of CSU 
patients with omalizumab 300 mg for 12 weeks was 
associated with reduced free IgE, consistent with the 
effect seen in asthma patients.[39] A statistically 
significant reduction in levels of FcɛRI+ cells in the 
dermis of non-lesional and lesional skin was observed 
and these results were temporally associated with the 
plateau of the improvement in clinical response. 
Reduction in FcɛRI+ cells was also observed in a 
previous study of skin biopsies from patients with 
allergic rhinitis [4], and would be expected as FcεRI+ 
cell density is dependent on free IgE, which decreases 
during omalizumab treatment. IgE+ cells in the dermis 
of non-lesional and lesional skin also decreased 
following omalizumab treatment although this 
decrease was not statistically significant. The decrease 
in IgE+ cells was also expected, as omalizumab binds 
to free IgE and prevents it binding to FcεRI. 
Subsequently, FcεRI are down-regulated [5]. Levels of 
FcεRI+ and IgE+ cells in omalizumab-treated patients 
at Week 12 had reduced to levels of those seen in 
healthy subjects at baseline. Overall, these results 
demonstrate that the systemic effects of omalizumab 
lead to local changes in the skin and there seems to be 
no difference in FceRI+ and IgE levels between 
affected (lesional) and unaffected (non-lesional) skin. 
While the mode of action of omalizumab in CSU 
patients is not fully understood, there are a few key 
hypotheses. One is that the density of IgE receptors at 
the surface of mast cells and basophils is proportional 
to the plasma-free IgE level [40]. Omalizumab binds 
to the same region on IgE as FcεRI [41], reducing free 
IgE to near undetectable levels. This should therefore 
down-regulate the FcεRI receptors so that e.g. 
potentially relevant IgG autoantibodies cannot 
cross-link FcεRI [42]. Cell activation would be 
suppressed, as would all the subsequent 
inflammatory processes. As a consequence, the 
frequency and severity of symptoms of CSU should 
be markedly diminished. This would account for a 
therapeutic effect of omalizumab in the 
approximately 30% of CSU patients with such 
autoantibodies. However, in patients without 
detectable autoantibodies, IgE and FcεRI seem to play 
an important role as well, as demonstrated by the 
efficacy of omalizumab in this population [43].  
It has also been suggested that down-regulation 
of FcεRI may be accompanied by an increase in the 
threshold above which degranulation of mast cells is 
triggered [44, 45]. This may be an independent 
mechanism of action, unrelated to prevention of 
cross-linkage of surface receptors. For degranulation 
to occur, a threshold number of receptors would need 
to be activated. The fall in free IgE after omalizumab 





treatment (both in the circulation and in tissue) and 
the reduction in the receptor density might therefore 
increase the threshold for degranulation to a much 
higher set point. Therefore, these two mechanisms 
may complement each other.  
The efficacy of omalizumab in this study was 
similar to that observed in Phase III studies [9, 10]. 
Statistically significant and clinically meaningful 
reductions in UAS7 scores were observed over 12 
weeks of treatment, with a mean decrease relative to 
placebo of -14.82 at Week 12. UAS7 decreased rapidly, 
with changes evident by one week after the first dose. 
Defining response to treatment as a 90% reduction in 
UAS7 from baseline, more than half of patients 
responded during the study, in line with that reported 
in key clinical studies of omalizumab [46]. Other 
clinical endpoints also showed improvements, 
including the physicians’ and patients’ global 
assessment scores, itch and hives assessment scores, 
percentage of angioedema-free days and use of rescue 
medication. Quality of life assessments (CU-Q2OL 
overall score, DLQI overall score and Skindex-29 
score) also showed improvements. The observed 
correlations of FcεRI-positive skin cells with UAS7 
scores point to the relevance of these cells in CSU and 
further supports the observation that reducing these 
cells is linked to the mode of action and clinical 
efficacy of omalizumab. 
Omalizumab decreases serum free IgE levels, 
and is associated with decreases in FcεRI+ cells and 
IgE+ cells in lesional and non-lesional skin (dermis) of 
patients with CSU. These results support the 
hypothesis that one mode of action of omalizumab in 
CSU involves reduction of free IgE, resulting in a 
down-regulation of surface IgE receptors, and 
subsequent reduction in downstream signaling via 
the FcεRI pathway [42]. However, the clinical 
response to omalizumab defined e.g. by UAS7 change 
seems to occur much faster than the histological 
changes in the skin. Therefore, further mechanisms 
might be involved in the omalizumab mode of action. 
Interestingly, the reduction of FcεRI and IgE positive 
peripheral basophils was much quicker and more 
closely reflected by the clinical response. This might 
be the result of an exchange of cells between different 
compartments (e.g. skin and blood). Importantly, 
changes in basophil parameters after omalizumab 
treatment were quick in onset like the decrease of free 
IgE but they were not indicative of clinical response as 
there was no correlation between basophil parameters 
and UAS7 (data not shown). Further investigations 
are required to determine the role and observed 
changes of peripheral basophils in CSU. 
In conclusion, omalizumab was effective and 
well-tolerated in the treatment of CSU patients in this 
study, consistent with the results of earlier Phase II 
and III studies. While the results of this exploratory 
study do require verification and extension in a larger 
and appropriately powered investigation, the data 
suggest that the decrease in free IgE, resulting from 
omalizumab treatment, may lead to a reduction in 
FcεRI+ cells and IgE+ cells in the dermis (to levels seen 
in healthy subjects). In addition, the changes observed 
in omalizumab-treated patients in peripheral blood 
basophils, in terms of basophil numbers, FcεRI 
expression and responsiveness of basophils to 
activating stimulation by anti-IgE, may also be 
involved in the therapeutic effect of omalizumab. This 
is the first report demonstrating that the clinical effect 
of omalizumab correlates with histopathological 
markers. 
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